NCT06268535View on ClinicalTrials.gov

Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study

CompletedOBSERVATIONAL
Enrollment

36,580,288

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Heart FailureCancer, Therapy-Related
Interventions
DRUG

Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023

Disproportionality analysis studying the association between cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023 and heart failure or cardiac dysfunction in the World Health Organization pharmacovigilance database.

Trial Locations (1)

Unknown

Caen University Hospital, Caen

All Listed Sponsors
lead

University Hospital, Caen

OTHER